Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance

Xeris Biopharma Holdings, Inc.

2025-FY EPS reported $0.00 revenue$291,845,000

Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.
Q4 Recorlev net revenue $45M; full-year Recorlev net revenue $139M.
Gvoke revenue grew >13% YoY; Keveyis patient base expanded vs. year-end 2024.
Positive Adjusted EBITDA delivered in each quarter of 2025.
Full 2025 results and 2026 outlook to be released March 2, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.